BAKU, Azerbaijan, Feb.8
Iran is expected to start a human trial of the COVID-19 vaccine in form of injection and inhalation that reconstructs a harmless piece of the virus’s spike protein.
The following vaccine Razi COV-Pars is an mRNA vaccine is made by the Razi Vaccine and Serum Research Institute and is the second Iranian coronavirus vaccine that will be tested in human trials after obtaining a permit from Iran’s Food and Drug Administration, Trend reports citing IRNA.
The 10 microgram dose of the vaccine would be injected into the muscle and the second phase would be injected 21 days later while an inhaling booster would be sprayed inside the nose 51 days after the first injection.
The vaccine will be tested on 130 volunteers in four groups.
The Secretary of the National Ethics Committee in Medical Sciences Research in the Ministry of Health has recently announced that clinical trial of the first phase of coronavirus vaccine made by the Razi Vaccine and Serum Research Institute was approved by the medical science committee.
"The most important step in starting a clinical trial of the second Iranian vaccine has been taken and the Food and Drug Administration would issue testing permit soon.
Iran’s first vaccine, COVIran Barekat, has completed its first phase of human trials on Sunday and the vaccine administered to 56 volunteers.
The human trials for the local two-dose vaccine had begun in late December and officials have said the early results will be published in less than a month.